Leukaemia diagnosis – Realising the potential of whole transcriptome sequencing

15. March 2022

In AML and ALL the application of WHO classification and ELN guidelines requires a plethora of methods to determine the diagnostic and prognostic subgroup. Especially in ALL, many different subtypes have been described, which makes accurate diagnosis a challenge. However, in recent years, whole genome and whole transcriptome sequencing have emerged as comprehensive high-throughput techniques that allow for an accurate genetic characterization. This identification of patients’ genetic fingerprint is key to a precise diagnosis and the design of personalised cancer treatments.

Building on our research we now aim to use whole genome sequencing (WGS) and whole transcriptome sequencing (WTS) to prospectively profile patients with a suspected diagnosis of ALL and AML. The study will allow us to increase our knowledge on the incidence of chromosome aberrations, somatic mutations, and altered gene expression profiles. Moreover, WGS & WTS allow an in-depth characterization of a patients’ genetic profile, providing the basis for more precise disease classification, prognosis and targeted treatment selection. Combining the different data layers will help to advance precision medicine and will allow us to provide each patient with the best possible diagnosis. 

Moreover, with the introduction of high-throughput sequencing techniques and the accompanied analysis of large gene panels and even whole genomes and transcriptomes, molecular genetics has entered the realm of big data. Hence, to get the most out of these comprehensive data sets, the implementation of machine learning methods to analyze these datasets is almost inevitable. We hope that the acquisition of large quantities of high-quality, standardized data will also contribute to successful downstream artificial intelligence (AI)-based methods, eventually transforming the multi-modal data into predictive models and decision-making tools.

Our efforts were recently summarized in Research Features magazine - enjoy the reading!

The author

»Do you have questions regarding this article or do you need further information? Please send me an e-mail.«

Dr. Wencke Walter

Bioinformatician, M.Sc.
Head of Innovation Department

T: +49 89 99017-545

You might also be interested in

Prof. Dr. med. Dr. phil. Torsten Haferlach
at 19.12.2024

Growth, Progress, and Gratitude: 2024 Annual Review

MLL MVZ looks back on a year full of milestones. In our year in review, we provide information on new diagnostic methods, personalised patient care, the nationwide specimen transport service and other highlights from 2024.

Read more

Dr. rer. nat. Katharina Hörst
at 18.12.2024

The MLL at the 66th ASH Annual Meeting & Exposition – A Recap

The 66th Annual Meeting & Exposition of the American Society of Hematology (ASH) was held in San Diego, California from 7 to 10 December. In this article, we take a look at the highlights of the seven papers presented by MLL at this year's ASH.

Read more

Julia Hennig
at 18.12.2024

KIM-Mail: A Secure Communication Channel for Medical Data

Conventional e-mail is not suitable for transmitting sensitive patient data. We are also interested in replacing analogue methods of transmitting reports, especially fax. This is why we have established the use of KIM-Mail in addition to our findings portal.

Read more